Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces its unaudited interim results for the six months ended 30 June 2020 and changes in its outlook for the second half.
Peter Keeling, Diaceutics’ Chief Executive, commented:
“In the first half of the year we have grown our client base, revenue and global reach and, at the same time, initiated innovation via our investments in data analytics and the introduction of our proprietary diagnostic network for precision medicine. However, all aspects of the healthcare business have been impacted in unprecedented ways by COVID-19 and we first saw this in our EU and Asian implementation projects. We have had to adjust plans for the second half to address very recent decisions relating to deferred budgets on a number of our client brands and ongoing delays with access to laboratories. The fundamentals of the precision marketplace and its dependency on better testing remain strong.”
My continued thanks to everyone at Diaceutics and to the increased investor support we gained during the period. It is my belief that the ‘new normal’ emerging post pandemic will serve to further accelerate the use of real-world evidence and platform technologies thereby embedding precision testing as the essential component driving value for Pharma’s business model for the next decade.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
To view the full report click here
